Abstract: The present invention is directed to a self-emulsifying cannabidiol composition containing one or more surfactants. The present invention is further directed to a method of treating a disease comprising administering a composition of the present invention to a subject in need thereof. The present invention is further directed to a method of treating withdrawal symptoms.

Abstract: Disclosed herein, are, among other things, stable, pharmaceutically acceptable and ophthalmologically suitable reduced buffer content and reduced buffering capacity pilocarpine compound compositions. In aspects, such compositions comprise therapeutically effective amounts of a pilocarpine compound, an effective amount of a uniform buffer component, wherein the concentrations of pilocarpine compound and uniform buffer component are limited to specific relative amounts and wherein the uniform buffer component is defined by one or more markedly distinguishing characteristics from buffers used in developed pilocarpine products (e.g., a unique pKa and/or concentration). Aspects of the invention include compositions defined by unique concentrations of such and other ingredients. Such compositions surprisingly exhibit pharmaceutically acceptable stability and, in aspects, stability equal to or statistically significantly greater than that of one or more on-market/developed reference product(s).

Abstract: A cosmetic composition with enhanced water resistance, color intensity and color retention after exposure to water is disclosed herein. The composition comprises a water dispersible film former component, a skin adhesion promoter component, a color enhancer component, and one or more colorants. The synergy of the components contributes to the improved attributes of the composition.

Abstract: The present invention relates to compounds Formula (I): wherein Q, R2, R3, R4 and R5 are as defined herein. The invention further relates to compositions comprising said compounds, and methods of controlling weeds using said compounds and/or compositions.

Abstract: A method for preparing granules. A slurry containing solid API powder particles dispersed in a liquid is prepared. The slurry is fed to a granulator and mixed with a dry base powder within the granulator in order to produce a slurry/base powder mixture. The slurry/base powder mixture produced within the granulator is dried in order to obtain granules containing the solid API particles and the base powder.

Abstract: A nerve regeneration device comprising a bioresorbable conduit and a matrix contained therein having elongate pores aligned with the longitudinal axis of the conduit. The matrix comprises collagen, fibronectin, laminin-1, and laminin-2, wherein the amount, by weight, of laminin-1 or laminin-2 is greater than the amount of fibronectin in the matrix.

Abstract: Disclosed are a peptide capable of induced self-assembly by a bioactive molecule comprising a (i) hydrogelation-promoting amino acid sequence and (ii) an oligomerization sequence; compositions containing the peptide and, optionally, bioactive molecule; hydrogels formed thereby; and various methods of using the same.

Abstract: Compositions, devices and methods employing therapeutic concentrations of a triptan for treatment of migraine are described. Also described are methods and apparatuses for delivery of zolmitriptan for achieving a Tmax as quick as 2 minutes and not later than 30 minutes in the majority of subjects.

Abstract: The kaolinite composite diagnostic and therapeutic agent uses modified kaolinite as a carrier and is loaded with carbon nitride quantum dots and doxorubicin. The present disclosure provides a preparation method of the kaolinite composite diagnostic and therapeutic agent, including the following steps: S1: preparing the modified kaolinite by subjecting the pharmaceutical grade kaolinite to intercalation, exfoliation, and immersion wet etching; S2: subjecting the modified kaolinite and a carbon nitride quantum dot solution to ultrasonication, drying, and grinding to obtain a kaolinite composite containing the carbon nitride quantum dots; and S3: dissolving the doxorubicin in the dark, adding dissolved doxorubicin into the kaolinite composite containing the carbon nitride quantum dots, shaking in the dark for a period of time, and washing and drying to obtain the diagnostic and therapeutic agent containing the carbon nitride quantum dots and the doxorubicin.

Abstract: Provided is a nanoparticle comprising a pH-responsive polymer, a pH-insensitive polymer and a payload molecule. The nanoparticle can act as a system for delivery of the payload that releases the payload in a pH sensitive manner.

Abstract: A solid oral pharmaceutical composition is disclosed, which comprises: a first active ingredient, which is pitavastatin or a pharmaceutically acceptable salt thereof; a second active ingredient, which is ezetimibe or a pharmaceutically acceptable salt thereof; and at least one excipient, including a diluent, a stabilizing agent, a disintegrant, a binding agent, a sweetener, a lubricant, a glidant, a flavor, a coloring agent or a combination thereof.

Abstract: The present invention provides materials and methods of making materials, where at least one surface of the material utilizes an emulsion to controllably release active agents, which can include hydrophilic agents, into the surrounding environment. Preferably, the materials are ‘slippery’ in that liquid droplets and other compounds, such as aqueous fluids, organic compounds and microorganisms, are able to easily slide off the surface without adhering to the surface. The active agents released by the emulsion may include antimicrobial agents, antifungal agents, antibacterial agents and other molecules that can kill or otherwise reduce the number of the pathogens. The resulting materials have improved anti-fouling behaviors compared to many other existing types of anti-fouling surfaces.

Abstract: The present disclosure relates to, inter alia, a formulation comprising one or more active agents and one or more thermal stabilizing agents and is co-mingled with a first propellant that is a gas propellant prior to being filled under pressure into said package; the first propellant is added in sufficient amounts to be dispersed in the formulation; the package is under sufficient pressure suitable to expel the formulation as a whipped formulation upon application of external force on said formulation in said package. The present disclosure also relates to, inter alia, a method of preparing the disclosed formulation; a package comprising the disclosed formulation, and a method of using the disclosed formulation.

Abstract: Tissue product compositions and methods for treating a patient are provided. The tissue product composition may include a flowable carrier including a hyaluronic acid based material and acellular tissue matrix particles mixed within the carrier. Methods of producing the tissue product composition and an injection device filled with the tissue product composition are also provided.

Abstract: The disclosure provides chewable nicotine formulations comprising an orally-acceptable nicotine salt, an orally-acceptable alcohol, flavor components, and an orally-acceptable binder in a water-permeable, water-insoluble pouch, together with methods of making and using the same.

Abstract: A sugar-responsive gel that is highly resistant to temperature changes, and a sugar-responsive drug delivery device including such a gel. The sugar-responsive gel, which comprises a gel composition including a monomer having a hydroxyl group in addition to a phenylboronic-acid-based monomer, can exhibit suitable temperature resistance. A sugar-responsive drug delivery device including such a sugar-responsive gel is less susceptible to the effects of temperature changes, and therefore can prevent undesirable excessive delivery of a drug such as insulin.

Abstract: The present disclosure generally relates to compositions and method for delivery, e.g., sustained delivery of active agents, and their use for the treatment of diseases or disorders.

Abstract: The present invention provides for an oral liquid suspension that includes quetiapine or a pharmaceutically acceptable salt thereof. Also provided is a method for orally delivering quetiapine fumarate to a subject (e.g., for treating a mental disorder in a subject, such as schizophrenia, bipolar mania, and/or bipolar depression). The method includes orally administering to the subject an oral liquid suspension described herein.

Abstract: The invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example.

Abstract: This invention provides novel oral dosage forms comprising a hops extract. The oral dosage forms are capable of activating bitter taste receptors expressed in the gastrointestinal tract. The applications include but are not limited to the use of the oral dosage forms for reducing energy intake and/or appetite in a subject.